Orthofix Medical Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ORTHOFIX MEDICAL INC. | ||
| Dated: March 5, 2024 | By: | /s/ MASSIMO CALAFIORE |
|---|---|---|
| Name: | Massimo Calafiore | |
| Title: | President and Chief Executive Officer, Director | |
| Dated: March 5, 2024 | By: | /s/ JULIE ANDREWS |
| Name: | Julie Andrews | |
| Title: | Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ MASSIMO CALAFIOREMassimo Calafiore | President and Chief Executive Officer, Director(Principal Executive Officer) | March 5, 2024 |
| /s/ JULIE ANDREWS Julie Andrews | Chief Financial Officer(Principal Financial and Accounting Officer) | March 5, 2024 |
| /s/ CATHERINE BURZIKCatherine Burzik | Director, Chair of the Board | March 5, 2024 |
| /s/ ALAN BAZAARAlan Bazaar | Director | March 5, 2024 |
| /s/ WAYNE BURRISWayne Burris | Director | March 5, 2024 |
| /s/ STUART ESSIGStuart Essig | Director | March 5, 2024 |
| /s/ MICHAEL FINEGAN | Director | March 5, 2024 |
| Michael Finegan | ||
| /s/ JASON HANNONJason Hannon | Director | March 5, 2024 |
| /s/ JOHN HENNEMAN, III | Director | March 5, 2024 |
| John Henneman, III | ||
| /s/ JAMES HINRICHS | Director | March 5, 2024 |
| James Hinrichs | ||
| /s/ CHARLES KUMMETH | Director | March 5, 2024 |
| Charles Kummeth | ||
| /s/ SHWETA SINGH MANIAR | Director | March 5, 2024 |
|---|---|---|
| Shweta Singh Maniar | ||
| /s/ MIKE PAOLUCCI | Director | March 5, 2024 |
| Mike Paolucci | ||
Statement of Management’s Responsibility for Financial Statements
To the Shareholders of Orthofix Medical Inc.:
Management is responsible for the preparation of the consolidated financial statements and related information that are presented in this Annual Report. The consolidated financial statements, which include amounts based on management’s estimates and judgments, have been prepared in conformity with accounting principles generally accepted in the United States. Other financial information in the report to shareholders is consistent with that in the consolidated financial statements.
The Company maintains accounting and internal control systems to provide reasonable assurance at a reasonable cost that assets are safeguarded against loss from unauthorized use or disposition, and that the financial records are reliable for preparing financial statements and maintaining accountability for assets. These systems are augmented by written policies, an organizational structure providing division of responsibilities, and careful selection and training of qualified personnel.
The Company engaged Ernst & Young LLP, independent registered public accountants, to audit and render an opinion on the consolidated financial statements in accordance with auditing standards of the Public Company Accounting Oversight Board (United States). These standards include an assessment of the systems of internal controls and tests of transactions to the extent considered necessary by them to support their opinion.
The Board of Directors, through its Audit Committee, consisting solely of outside directors of the Company, meets periodically with management and our independent registered public accountants to ensure that each is meeting its responsibilities and to discuss matters concerning internal controls and financial reporting. Ernst & Young LLP has full and free access to the Audit Committee.
James Hinrichs
Chairman of the Audit Committee
Massimo Calafiore
President and Chief Executive Officer, Director
Julie Andrews
Chief Financial Officer
Index to Consolidated Financial Statements
| Page | ||
| Index to Consolidated Financial Statements | F-1 | |
|---|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-5 | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022, and 2021 | F-6 | |
| Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2023, 2022, and 2021 | F-7 | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022, and 2021 | F-8 | |
| Notes to the Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.